• Established parallel synthesis capabilities at AstraZeneca to allow the rapid prosecution of screening hits and the development of SAR in discovery projects.
    • Directed the Joint Research Committee for the Broad Collaboration at AstraZeneca. Led drug discovery collaboration utilizing the Broad Institute's unique 100K member Diversity Oriented Synthesis library for antibacterial and antiviral drug discovery efforts. Developed a novel inhibitor of DNA gyrase with activity against Pseudomonas aeruginosa.
    • Managed a US$2.5 million global project to design and synthesize a unique collection of compounds targeting NAD utilizing enzymes. This initiative produced more than 20,000 compounds for AstraZeneca’s corporate screening collection that target this important class of enzymes and has resulted in project starts in this emerging disease area.

    Includes matters handled at Dechert or prior to joining the firm.

    • University of Bremen, Germany, 1986
    • University of Maryland, B.S., 1987, magna cum laude, high honors in Chemistry
    • Massachusetts Institute of Technology (MIT), Ph.D., Organic Chemistry, 1993
    • National Institutes of Health, Post-Doctoral Fellowship, 1997
    • Wilmington University, M.B.A., 2013
    • United States Patent and Trademark Office